The presentation by Precision’s Marlon Graf of a study with Jim Baumgardner, Iris Brewer, Jacquelyn Chou and Oliver Diaz and their colleagues was named an ISPOR 2023 Research Presentation Award Finalist. The Generalized Risk-Adjusted Cost-Effectiveness framework is a generalization of conventional cost-effectiveness analysis (CEA) and incorporates the effects of diminishing returns to health improvements as severity of illness increases. In the study presented by Marlon, the GRACE framework was applied to assess the comprehensive value of direct-acting antivirals (DAAs) for the treatment of hepatitis C (HCV) compared to peginterferon alfa and ribavirin (PEG/riba), accounting for differential valuations of life years versus quality of life, disease severity, insurance value, and other novel value elements. Please reach out to Marlon to learn more about the GRACE framework.